hHepc constitutively overexpressed in mice was neutralized by Ab2.7. (A) Experimental scheme detailing administration time of hepcidin (or control) virus (AAV5) with dosing schemes for antihepcidin (or control) antibody (1 mg subcutaneously: n = 5/group). Sampling for panel B (serum iron) is shown in blue. Extra treatment (ESA: 100 μg/kg subcutaneous darbepoetin alfa) and samplings for panel C are shown in red. (B) AAV-hHepc (1.5 × 10¹² particles/mouse) caused a serum iron decrease compared with control virus treatment (AAV-β-galactosidase), which was prevented by Ab2.7 treatment in a dose-responsive manner. Statistical differences compared with AAV-hHepc + control antibody (□) are shown. (C) Control virus-treated mice (AAV-GFP; 5 × 10¹² particles/mouse) showed a normal response to ESA, whereas those expressing AAV-hHepc did not. Ab2.7 restored response to ESA in AAV-hHepc mice in a dose-responsive manner. Statistics represent comparison of Hb values at day 21. Significant differences from AAV-hHepc + 5X control Ab + ESA (blue line) are shown. For statistical comparisons, **P < .01; ***P < .001.